Paul M. Barr - Concepedia

Author

Paul M. Barr

University of Rochester ORCID

Also Known As

Barr, Paul M., Forman, Stephen J., P Barr, P M Barr, P. Barr, P. M Barr, P. M. Barr, P.M. Barr, Paul Barr, Paul M Barr

451

Publications

16.3K

Citations

H-Index

Concepts

All Affiliations

University of Rochester University of Rochester Medical Center The University of Texas MD Anderson Cancer Center Cornell University Stanford University

About

Paul M. Barr is an author at University of Rochester specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	39	3.3K
2	Health Sciences	15	19	985
3	Cell Biology	3	3	99
4	Social Sciences	1	1	13
5	Blood Transplantation	1	1	61

Paul M. Barr

129

Publications

14.8K

Citations

H-Index

Page 1

	Year	Citations
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia John C. Byrd, Jennifer R. Brown, Susan O’Brien, New England Journal of Medicine	2014	1.6K
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, New England Journal of Medicine	2015	1.5K
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma Wyndham H. Wilson, Ryan M. Young, Roland Schmitz, Nature Medicine Lymphoid NeoplasiaMedicineImmunologyPathologyImmune Checkpoint Inhibitor	2015	1.1K
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, New England Journal of Medicine	2018	927
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia Tait D. Shanafelt, Xin V. Wang, Neil E. Kay, New England Journal of Medicine	2019	715
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma Talha Munir, Jennifer R. Brown, Susan O’Brien, American Journal of Hematology	2019	451
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study Jan A. Burger, Paul M. Barr, Tadeusz Robak, Leukemia	2019	447
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Haematologica	2018	439
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial Jeffrey A. Jones, Anthony R. Mato, William G. Wierda, The Lancet Oncology Hematological MalignancyInterim AnalysisLymphoid NeoplasiaMedicineImmunology	2017	372
Outcomes of COVID-19 in patients with CLL: a multicenter international experience Anthony R. Mato, Lindsey E. Roeker, Nicole Lamanna, Blood	2020	316

Page 1